Starting December 15, 2025, SafeRide Health will become the new provider for all member rides to doctor appointments and pharmacy visits. After this date, Texas Children’s Health Plan will no longer use MTM for Non Emergency Medical Transportation (NEMT) services.
For other questions, please call Member Services at the number on the back of your member ID card.
A partir del 15 de diciembre de 2025, SafeRide Health será el nuevo proveedor para todos los viajes de los miembros a citas médicas y visitas a la farmacia. Después de esta fecha, Texas Children’s Health Plan ya no usará MTM para los servicios de Transporte Médico No Urgente (NEMT).
Call to action: Texas Children’s Health Plan (TCHP) would like to inform providers that effective April 3, 2023, the Texas Health and Human Services Commission (HHSC) temporarily removed the non-preferred status from the generic product, Lidocaine 5% patches on the preferred drug list (PDL). The preferred status of the brand name products (NDC 63481-0687-06) will not change to allow for any existing stock available to be utilized. This is in response to drug shortage for Lidoderm patches (PDL) due to discontinuation of the product by the manufacturer.
Please see below the NDC for Lidocaine 5% patch that will be recognized on the PDL.
PREFERRED AGENTS
NDC
Generic Drug Name
00378905593
Lidocaine 5% patch
00591352530
Lidocaine 5% patch
00603188016
Lidocaine 5% patch
16714017730
Lidocaine 5% patch
42858011830
Lidocaine 5% patch
65162079108
Lidocaine 5% patch
How this impacts providers: The change will allow providers to prescribe the generic lidocaine patches without requiring a PDL prior authorization. Providers will be able to continue prescribing necessary medication to their patients.
NOTE: This change is temporary. HHSC will further assess the availability of any alternative brand name products in the Neuropathic Pain PDL class. HHSC will provide further announcements regarding future PDL status changes when information becomes available.
Next steps for providers: Prescribers are encouraged to proactively obtain a prescription for the preferred agents.
